Table 2 Antimicrobial drugs whose development has utilized computational and artificial intelligence (AI) technologies

SPR206

Completed Phase I

SAR-based design

CRAB, CRPA, CRKP

QPX 9003

Phase I

SAR combining with STR and SPR-based design

CRAB, CRPA, CRKP

MRX-8

Phase I

Soft drug design

CRAB, CRPA, CRKP

IB-367 (iseganan)

Failed in Phase III

Molecular dynamics simulation

Gram-negative and Gram-positive pathogens and Candida albicans

Reltecimod (AB103)

Phase III

Molecular dynamics simulation, binds to the CD28 receptor

Modulate the host’s immune response in severe Gram-negative bacterial infections

Murepavadin

Terminated Phase III

Protein epitope mimetics

CRPA

Bactenecin

Preclinical

Machine-learning classifier

P. aeruginosa

Indolicidin analogue CP-11

Preclinical

Biophysically motivated modeling

Gram-negative and Gram-positive pathogens, fungi, and viruses

Halicin

Preclinical

Drug repurposing Hub

M. tuberculosis, C. difficile, A. baumannii, and CRE